Five Big Drug Results in Four Days: What the ADA 2026 Meeting Told Us

Once a year, the American Diabetes Association holds a meeting where drug companies share their latest results. This year it ran from June 5 to 8, 2026, in New Orleans, and it was one of the busiest in memory for weight loss and diabetes drugs. Five separate late-stage drug programs reported results, several of them published in medical journals the same week.

For anyone trying to follow this fast-moving field, it can be a lot to take in. Below is a simple breakdown of the five that got the most attention, and what each one means.

1. Orforglipron: a GLP-1 you swallow

Almost every GLP-1 drug today is a shot. Orforglipron is a pill. That is the headline. A daily tablet that works like the injected drugs would be easier to make, easier to ship, and easier for people who do not want needles. If a pill can come close to the results of the shots, it could open the door to a lot more people. This is one of the most watched stories in the whole field right now.

2. Retatrutide: pushing weight loss to new highs

Retatrutide is Eli Lilly's triple-hormone drug, meaning it works on three different targets at once instead of one or two. In earlier studies it produced some of the largest weight loss numbers anyone had seen from a drug. At this meeting, Lilly shared full late-stage results in people with type 2 diabetes. It remains one of the strongest options in the pipeline for people who need to lose a significant amount of weight.

3. CagriSema: two drugs combined into one

CagriSema is Novo Nordisk's combination of semaglutide (the Wegovy ingredient) and a second drug called cagrilintide. The idea is that two appetite-control pathways working together can do more than either alone. It is Novo's answer to the growing competition and aims to keep the company near the front of the weight loss race.

4. Survodutide: built with the liver in mind

Survodutide works on two hormone targets and is being studied not just for weight, but for a serious liver condition tied to obesity, sometimes called fatty liver disease. This points to a wider trend: these drugs are no longer only about weight on a scale. Researchers are testing whether they can also protect organs and prevent other diseases that come with extra weight.

5. Evolocumab: a reminder it is not all about GLP-1

Evolocumab is a different kind of drug. It lowers cholesterol rather than controlling appetite. Its appearance at the meeting is a useful reminder that managing diabetes and heart risk takes more than one type of medicine. Weight loss drugs grab the headlines, but they work alongside other treatments, not in place of them.

The pattern behind the news

Step back and a clear theme appears. The first generation of these drugs proved that they work. The race now is about making them better and easier to live with: a pill instead of a shot, drugs that target more pathways at once, and drugs that protect the heart and liver, not just trim weight. We saw the same convenience push in Pfizer's once-a-month GLP-1 results from this same meeting.

This explosion of new drugs is also reshaping the business side of medicine, which we covered when telehealth companies started building their own peptide pipelines and supply deals. And it sits on top of a shifting set of rules, including the FDA's 2026 changes to how certain peptides can be prescribed.

One honest note to close on. Strong results at a conference are a promising sign, not a finished story. Drugs still have to clear final trials, win approval, and prove themselves over the long run before they reach most patients. But after a week like this one, the direction of travel is hard to miss: more options, more competition, and treatments that keep getting easier to take.

Source: Tech Times: GLP-1 Drugs 2026, ADA Sessions Close as New Standards End Single-Goal Diabetes Care (8 Jun 2026)